PE20050465A1 - QUINUCLIDINE DERIVED COMPOUNDS AS ANTAGONISTS OF THE MUSCARINE M3 RECEPTOR - Google Patents
QUINUCLIDINE DERIVED COMPOUNDS AS ANTAGONISTS OF THE MUSCARINE M3 RECEPTORInfo
- Publication number
- PE20050465A1 PE20050465A1 PE2004000435A PE2004000435A PE20050465A1 PE 20050465 A1 PE20050465 A1 PE 20050465A1 PE 2004000435 A PE2004000435 A PE 2004000435A PE 2004000435 A PE2004000435 A PE 2004000435A PE 20050465 A1 PE20050465 A1 PE 20050465A1
- Authority
- PE
- Peru
- Prior art keywords
- azonia
- acetoxy
- octane
- bicycle
- diphenyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
SE REFIERE A COMPUESTOS DERIVADOS DE QUINUCLIDINA DE FORMULA (I), DONDE R1 Y R3 SON INDEPENDIENTEMENTE, CARBOCICLICO (C3-C15), O UN HETEROCICLO DE 4 A 12 MIEMBROS Y POR LO MENOS CON UN ANILLO HETEROGENEO SELECCIONADO DE N, O Y S; O -CR1R2R3 JUNTOS FORMAN UN GRUPO DE FORMULA (i) DONDE R ES -O-, -S-, -CH2-, -CH=CH-, -CH2-CH2-, AMINO O -N(CH3)-; R2 ES H, HALOGENO, -OH, ALCOXI O ALQUILO(C1-C8); R4 ES ALQUILO(C1-C8) SUSTITUIDO POR -NR5, -NR5-CO-R6, -NR5-CO-NH-R7-, ENTRE OTROS, O ES ALQUINILO(C3-C10), OPCIONALMENTE SUSTITUIDO. SON COMPUESTOS PREFERIDOS: TRIFLUOROACETATO DE (R)-3-(2-HIDROXI-2,2-DIFENIL-ACETOXI)-1-[3-(3-FENIL-UREIDO)-PROPIL]1-AZONIA-BICICLO[2,2,2]-OCTANO, (R)-3-(2-HIDROXI-2,2-DIFENIL-ACETOXI)-1-FENILCARBAMOILMETIL-1-AZONIA-BICICLO[2,2,2]-OCTANO, BROMURO DE (R)-3-(2-FLUORO-2,2-DIFENIL-ACETOXI)-1-FENOXICARBONILMETIL-1-AZONIA-BICICLO[2,2,2]-OCTANO, ENTRE OTROS. TAMBIEN SE REFIERE A PROCEDIMIENTO DE OBTENCION. ESTOS COMPUESTOS SON ANTAGONISTAS DEL RECEPTOR MUSCARINICO M3 Y PUEDEN PRESENTARSE EN COMBINACION CON UN ANTIINFLAMATORIO, BRONCODILATADOR, ANTIHISTAMINICO, ENTRE OTROS, Y SON UTILES PARA ELTRATAMIENTO DE ENFERMEDADES INFLAMATORIAS U OBSTRUCTIVAS DE LAS VIAS RESPIRATORIASREFERS TO COMPOUNDS DERIVED FROM QUINUCLIDINE OF FORMULA (I), WHERE R1 AND R3 ARE INDEPENDENTLY, CARBOCYCLIC (C3-C15), OR A HETEROCYCLE OF 4 TO 12 MEMBERS AND WITH AT LEAST ONE HETEROGENEOUS RING OR SELECTED FROM N; OR -CR1R2R3 TOGETHER FORM A GROUP OF FORMULA (i) WHERE R IS -O-, -S-, -CH2-, -CH = CH-, -CH2-CH2-, AMINO OR -N (CH3) -; R2 IS H, HALOGEN, -OH, ALCOXY OR (C1-C8) ALKYL; R4 IS ALKYL (C1-C8) REPLACED BY -NR5, -NR5-CO-R6, -NR5-CO-NH-R7-, AMONG OTHERS, OR IS ALKYL (C3-C10), OPTIONALLY SUBSTITUTED. PREFERRED COMPOUNDS ARE: (R) -3- (2-HYDROXY-2,2-DIPHENYL-ACETOXY) -1- [3- (3-PHENYL-UREIDE) -PROPYL] 1-AZONIA-BICYCLE TRIFLUOROACETATE [2,2 , 2] -OCTANE, (R) -3- (2-HYDROXY-2,2-DIPHENYL-ACETOXY) -1-PHENYLCARBAMOYLMETHYL-1-AZONIA-BICYCLE [2,2,2] -OCTANE, (R) BROMIDE -3- (2-FLUORO-2,2-DIPHENYL-ACETOXY) -1-PHENOXYCARBONYLMEthyl-1-AZONIA-BICYCLE [2,2,2] -OCTANE, AMONG OTHERS. IT ALSO REFERS TO OBTAINING PROCEDURE. THESE COMPOUNDS ARE ANTAGONISTS OF THE MUSCARINIC M3 RECEPTOR AND MAY BE PRESENT IN COMBINATION WITH AN ANTI-INFLAMMATORY, BRONCHODILATOR, ANTIHISTAMINE, AMONG OTHERS, AND ARE USEFUL FOR THE TREATMENT OF INFLAMMATORY OR OBSTRUCTIVE INFLAMMATORY DISEASES
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0310232 | 2003-05-02 | ||
| GB0324887A GB0324887D0 (en) | 2003-10-24 | 2003-10-24 | Organic compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20050465A1 true PE20050465A1 (en) | 2005-07-18 |
Family
ID=33420896
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2004000435A PE20050465A1 (en) | 2003-05-02 | 2004-04-30 | QUINUCLIDINE DERIVED COMPOUNDS AS ANTAGONISTS OF THE MUSCARINE M3 RECEPTOR |
Country Status (31)
| Country | Link |
|---|---|
| US (2) | US20070060563A1 (en) |
| EP (1) | EP1631569B1 (en) |
| JP (1) | JP4416786B2 (en) |
| KR (1) | KR100896544B1 (en) |
| AR (1) | AR044134A1 (en) |
| AT (1) | ATE440840T1 (en) |
| AU (1) | AU2004234069B2 (en) |
| BR (1) | BRPI0410238A (en) |
| CA (1) | CA2523436C (en) |
| CL (1) | CL2004000918A1 (en) |
| CO (1) | CO5700782A2 (en) |
| CY (1) | CY1109655T1 (en) |
| DE (1) | DE602004022805D1 (en) |
| DK (1) | DK1631569T3 (en) |
| EC (1) | ECSP056134A (en) |
| ES (1) | ES2331185T3 (en) |
| HR (1) | HRP20050933A2 (en) |
| IL (1) | IL171591A (en) |
| IS (1) | IS2746B (en) |
| MA (1) | MA27775A1 (en) |
| MX (1) | MXPA05011739A (en) |
| MY (1) | MY142652A (en) |
| NO (1) | NO20055688L (en) |
| NZ (1) | NZ542995A (en) |
| PE (1) | PE20050465A1 (en) |
| PL (1) | PL1631569T3 (en) |
| PT (1) | PT1631569E (en) |
| RU (1) | RU2363700C2 (en) |
| SI (1) | SI1631569T1 (en) |
| TW (1) | TWI340139B (en) |
| WO (1) | WO2004096800A2 (en) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2239546B1 (en) * | 2004-03-15 | 2006-12-01 | Almirall Prodesfarma, S.A. | NEW QUATERNIZED QUINUCLIDINE ESTERS. |
| GB0410712D0 (en) | 2004-05-13 | 2004-06-16 | Novartis Ag | Organic compounds |
| GB0424284D0 (en) * | 2004-11-02 | 2004-12-01 | Novartis Ag | Organic compounds |
| GB0428416D0 (en) | 2004-12-24 | 2005-02-02 | Novartis Ag | Organic compounds |
| GB0601951D0 (en) | 2006-01-31 | 2006-03-15 | Novartis Ag | Organic compounds |
| EP1894568A1 (en) * | 2006-08-31 | 2008-03-05 | Novartis AG | Pharmaceutical compositions for the treatment of inflammatory or obstructive airway diseases |
| EP1900737A1 (en) * | 2006-08-31 | 2008-03-19 | Novartis AG | Polymorph of (R)-3-(2-hydroxy-2,2-diphenyl-acetoxy)-1-(isoxazol-3-ylcarbamoyl-methyl)-1-azonia-bicyclo-[2.2.2]octane bromide |
| TW200825084A (en) * | 2006-11-14 | 2008-06-16 | Astrazeneca Ab | New compounds 521 |
| JP4604129B2 (en) * | 2006-12-19 | 2010-12-22 | アストラゼネカ・アクチエボラーグ | Quinuclidinol derivatives as muscarinic receptor antagonists |
| EP1950196A1 (en) * | 2007-01-29 | 2008-07-30 | Boehringer Ingelheim Pharma GmbH & Co. KG | Method for manufacturing ammonium hexafluorphosphates |
| KR101517574B1 (en) * | 2007-09-07 | 2015-05-07 | 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 | Guanidine-containing compounds useful as muscarinic receptor antagonists |
| US8017617B2 (en) | 2007-12-14 | 2011-09-13 | Theravance, Inc. | Amidine-containing compounds useful as muscarinic receptor antagonists |
| KR20100113557A (en) | 2008-01-11 | 2010-10-21 | 노파르티스 아게 | Pyrimidines as kinase inhibitors |
| BRPI0912657A2 (en) * | 2008-05-13 | 2016-01-26 | Astrazeneca Ab | pharmaceutical product comprising a muscarinic receptor antagonist and a beta2-adrenoreceptor agonist |
| GB0808709D0 (en) * | 2008-05-13 | 2008-06-18 | Astrazeneca Ab | New combination 295 |
| EA017627B1 (en) * | 2008-05-13 | 2013-01-30 | Астразенека Аб | Quinuclidine derivatives as muscarinic m3 receptor antagonists |
| US20090326004A1 (en) | 2008-06-03 | 2009-12-31 | Ranbaxy Laboratories Limited | Muscarinic receptor antagonists |
| WO2009153536A1 (en) * | 2008-06-17 | 2009-12-23 | Argenta Discovery Limited | 1-aza-bicyclo [2.2.2] octane derivatives useful as muscarinic receptor antagonists |
| GB0811100D0 (en) * | 2008-06-17 | 2008-07-23 | Astrazeneca Ab | New combination |
| CN102947300B (en) * | 2010-06-22 | 2016-09-21 | 奇斯药制品公司 | Alkaloid amino ester derivative and pharmaceutical composition thereof |
| US8637516B2 (en) | 2010-09-09 | 2014-01-28 | Irm Llc | Compounds and compositions as TRK inhibitors |
| WO2012034095A1 (en) | 2010-09-09 | 2012-03-15 | Irm Llc | Compounds and compositions as trk inhibitors |
| US9102671B2 (en) | 2011-02-25 | 2015-08-11 | Novartis Ag | Compounds and compositions as TRK inhibitors |
| JP2011195593A (en) * | 2011-06-30 | 2011-10-06 | Astrazeneca Ab | Quinuclidine derivative as muscarinic m3 receptor antagonist |
| KR20140105746A (en) * | 2011-12-30 | 2014-09-02 | 키에시 파르마슈티시 엣스. 피. 에이. | Quinuclidine esters of 1-azaheterocyclylacetic acid as antimuscarinic agents, process for their preparation and medicinal compositions thereof |
| US9687488B2 (en) | 2012-05-03 | 2017-06-27 | St. Louis College Of Pharmacy | Compositions and methods for increasing neurotrophic peptides |
| TWI647227B (en) * | 2013-02-28 | 2019-01-11 | 日商安斯泰來製藥股份有限公司 | 2-guanamine thiazole derivative or a salt thereof |
| CZ306791B6 (en) | 2013-10-29 | 2017-07-12 | Zentiva, K.S. | An industrially applicable process of preparing aclidinium bromide of high purity |
| PT108370B (en) * | 2015-03-30 | 2018-10-25 | Hovione Farm S A | ACLIDINE BROMETON PREPARATION PROCESS |
| ES2897697T3 (en) | 2015-07-03 | 2022-03-02 | Novartis Ag | Inhaler adapted to read information stored on a data storage medium of a container |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1219606A (en) * | 1968-07-15 | 1971-01-20 | Rech S Et D Applic Scient Soge | Quinuclidinol derivatives and preparation thereof |
| DK534178A (en) * | 1977-12-16 | 1979-06-17 | Interx Research Corp | ANTICHOLINERGIC AGENTS WITH SECTIONING EFFECT |
| IT1230881B (en) * | 1989-06-20 | 1991-11-08 | Angeli Inst Spa | DERIVATIVES OF R (-) 3-QUINUCLIDINOL |
| ES2165768B1 (en) * | 1999-07-14 | 2003-04-01 | Almirall Prodesfarma Sa | NEW DERIVATIVES OF QUINUCLIDINE AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM. |
| WO2002004402A1 (en) * | 2000-07-11 | 2002-01-17 | Banyu Pharmaceutical Co., Ltd. | Ester derivatives |
| DK1353919T3 (en) * | 2000-12-28 | 2006-11-20 | Almirall Prodesfarma Ag | Newly known quinuclidine derivatives and medicinal compositions containing the same |
| UA76571C2 (en) * | 2001-12-20 | 2006-08-15 | Derivatives of 1-alkyl-1-azoniabicyclo [2.2.2.]octanecarbamate and use thereof as antagonists of muscarin receptor | |
| GB0424284D0 (en) | 2004-11-02 | 2004-12-01 | Novartis Ag | Organic compounds |
| EP1900737A1 (en) * | 2006-08-31 | 2008-03-19 | Novartis AG | Polymorph of (R)-3-(2-hydroxy-2,2-diphenyl-acetoxy)-1-(isoxazol-3-ylcarbamoyl-methyl)-1-azonia-bicyclo-[2.2.2]octane bromide |
-
2004
- 2004-04-29 AR ARP040101468A patent/AR044134A1/en not_active Application Discontinuation
- 2004-04-30 PE PE2004000435A patent/PE20050465A1/en not_active Application Discontinuation
- 2004-04-30 RU RU2005137360/04A patent/RU2363700C2/en not_active IP Right Cessation
- 2004-04-30 DE DE602004022805T patent/DE602004022805D1/en not_active Expired - Lifetime
- 2004-04-30 BR BRPI0410238-0A patent/BRPI0410238A/en not_active IP Right Cessation
- 2004-04-30 PL PL04730519T patent/PL1631569T3/en unknown
- 2004-04-30 PT PT04730519T patent/PT1631569E/en unknown
- 2004-04-30 AT AT04730519T patent/ATE440840T1/en active
- 2004-04-30 ES ES04730519T patent/ES2331185T3/en not_active Expired - Lifetime
- 2004-04-30 DK DK04730519T patent/DK1631569T3/en active
- 2004-04-30 CL CL200400918A patent/CL2004000918A1/en unknown
- 2004-04-30 SI SI200431277T patent/SI1631569T1/en unknown
- 2004-04-30 JP JP2006505341A patent/JP4416786B2/en not_active Expired - Fee Related
- 2004-04-30 CA CA2523436A patent/CA2523436C/en not_active Expired - Fee Related
- 2004-04-30 KR KR1020057020776A patent/KR100896544B1/en not_active Expired - Fee Related
- 2004-04-30 US US10/554,558 patent/US20070060563A1/en not_active Abandoned
- 2004-04-30 TW TW093112339A patent/TWI340139B/en not_active IP Right Cessation
- 2004-04-30 AU AU2004234069A patent/AU2004234069B2/en not_active Ceased
- 2004-04-30 MX MXPA05011739A patent/MXPA05011739A/en active IP Right Grant
- 2004-04-30 NZ NZ542995A patent/NZ542995A/en not_active IP Right Cessation
- 2004-04-30 EP EP04730519A patent/EP1631569B1/en not_active Expired - Lifetime
- 2004-04-30 WO PCT/EP2004/004605 patent/WO2004096800A2/en not_active Ceased
- 2004-04-30 HR HR20050933A patent/HRP20050933A2/en not_active Application Discontinuation
- 2004-04-30 MY MYPI20041637A patent/MY142652A/en unknown
-
2005
- 2005-10-27 IL IL171591A patent/IL171591A/en not_active IP Right Cessation
- 2005-11-01 EC EC2005006134A patent/ECSP056134A/en unknown
- 2005-11-03 CO CO05112195A patent/CO5700782A2/en not_active Application Discontinuation
- 2005-11-08 MA MA28583A patent/MA27775A1/en unknown
- 2005-11-30 IS IS8158A patent/IS2746B/en unknown
- 2005-12-01 NO NO20055688A patent/NO20055688L/en not_active Application Discontinuation
-
2009
- 2009-10-20 US US12/582,291 patent/US8168654B2/en not_active Expired - Fee Related
- 2009-11-25 CY CY20091101230T patent/CY1109655T1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20050465A1 (en) | QUINUCLIDINE DERIVED COMPOUNDS AS ANTAGONISTS OF THE MUSCARINE M3 RECEPTOR | |
| EP0731802B1 (en) | N-substituted azabicycloalkane derivatives as neuroleptics etc. | |
| US5308854A (en) | Inhibitors of HIV reverse transcriptase | |
| JP5087171B2 (en) | 1- (Arylsulfonyl) -4- (piperazin-1-yl) -1H-benzimidazoles as 5-hydroxytryptamine-6 ligands | |
| US6316470B1 (en) | Benzylpiperazinyl and piperidinyl ethanone derivatives: dopamine receptor subtype specific ligands | |
| US8546402B2 (en) | Chromone derivatives, a process for their preparation and their therapeutic applications | |
| US20030008874A1 (en) | 1,3 disubstituted pyrrolidines as alpha -2- adrenoceptor antagonists | |
| AR006545A1 (en) | SUBSTITUTE COMPOUNDS FOR CATECOLAMINS, USEFUL AS BETA3 ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND INTERMEDIATE COMPOUNDS FOR EXCLUSIVE APPLICATION IN THE PREPARATION OF SUCH COMPOUNDS | |
| PE20001467A1 (en) | DERIVATIVES OF 4-PHENYLPYRIDINE AS ANTAGONISTS OF THE NEUROQUININ RECEPTOR | |
| EA199700156A1 (en) | INDOL DERIVATIVES AS ANTAGONISTS OF 5-HT RECEPTOR | |
| PE20040120A1 (en) | QUINOLINE DERIVATIVES AS ANTAGONISTS OF NPY | |
| CL2003002050A1 (en) | COMPOUNDS DERIVED FROM 1-PIPERAZIN-1,2-DIHYDROINDEN, ITS PHARMACEUTICAL COMPOSITION AND THE USE OF THIS TO TREAT DISEASES OF THE CENTRAL NERVOUS SYSTEM. | |
| PE20060483A1 (en) | HETEROCYCLIC COMPOUNDS AS ANTAGONISTS OF NK1 | |
| PE75199A1 (en) | QUINOLINE DERIVATIVE USEFUL AS A NEUROQUININE ANTAGONIST | |
| PE20060653A1 (en) | CONDENSED TRICYCLIC DERIVATIVES AS 5-HT1 RECEIVER MODULATORS | |
| AR052314A1 (en) | TIENOPIRIDINONE COMPOUNDS AS 5-HT4 RECEIVER AGONISTS | |
| MX2007004199A (en) | 5-sulfonyl-1-piperidinyl substituted indole derivatives as 5-ht6 receptor antagonists for the treatment of cns disorders. | |
| PE20081574A1 (en) | INDOL-2-IL-CARBONYL-PIPERIDINE DERIVATIVES AS ANTAGONISTS OF THE V1a RECEPTOR | |
| BR0009582A (en) | Compound, pharmaceutical composition, and, process for the treatment of a disease condition selected from rheumatoid arthritis, dealzheimer's disease, cancer, schizophrenia, edema, allergic rhinitis, inflammation, pain, gastrointestinal asthma, gastric asthma, refluxogastroesfageal, anxiety, emesis, dehuntingtones depression, hypertension, migraine and hives | |
| PE20051152A1 (en) | MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS M3 | |
| EP2616440A1 (en) | Arylosulfonamides for the treatment of cns diseases | |
| CN1136807A (en) | N-substituted azabicycloheptane derivatives their preparation and use | |
| US5908844A (en) | N-substituted azabicycloalkane derivatives, their preparation and use | |
| EA200501594A1 (en) | SUBSTITUTED DERIVATIVES OF AZABICOLOGEXANE AS ANTAGONISTS OF MUSCARINE RECEPTOR | |
| ATE263150T1 (en) | IL-8 RECEPTOR ANTAGONISTS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| FD | Application declared void or lapsed |